Regulatory Effect and Mechanism of Erythroblastic Island Macrophages on Anemia in Patients with Newly Diagnosed Multiple Myeloma

References

• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346. doi:10.1016/S1470-2045(16)30206-6
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. doi:10.1038/nrdp.2017.46
   PubMed Web of Science ®Google Scholar
• Paitan V, Alcarraz C, Leornado A, et al. Anemia Como Factor Pronóstico En Pacientes con Cáncer [Anemia as a prognostic factor in cancer patients]. Rev Peru Med Exp Salud Publica. 2018;35:250–258. Spanish doi:10.17843/rpmesp.2018.352.3171
   PubMedGoogle Scholar
• Solmaz S, Uzun O, Sevindik OG, et al. The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma. Int J Lab Hematol. 2023;45:13–19. doi:10.1111/ijlh.13958
   PubMed Web of Science ®Google Scholar
• Ludwig H, Zojer N. Supportive care in multiple myeloma. Best Pract Res Clin Haematol. 2007;20:817–835. doi:10.1016/j.beha.2007.10.001
   PubMed Web of Science ®Google Scholar
• Bessis M. Île érythroblastique, unité fonctionnelle de la moelle osseuse [Erythroblastic island, functional unity of bone marrow]. Rev Hematol. 1958;13:8–11. French
   PubMedGoogle Scholar
• Soni S, Bala S, Gwynn B, et al. Absence of erythroblast macrophage protein (Emp) leads to failure of erythroblast nuclear extrusion. J Biol Chem. 2006;281:20181–20189. doi:10.1074/jbc.M603226200
   PubMed Web of Science ®Google Scholar
• Rhodes MM, Kopsombut P, Bondurant MC, Price JO, Koury MJ. Adherence to macrophages in erythroblastic islands enhances erythroblast proliferation and increases erythrocyte production by a different mechanism than erythropoietin. Blood. 2008;111:1700–1708. doi:10.1182/blood-2007-06-098178
   PubMed Web of Science ®Google Scholar
• Chow A, Huggins M, Ahmed J, et al. CD169(+) macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med. 2013;19:429–436. doi:10.1038/nm.3057
   PubMed Web of Science ®Google Scholar
• Porcu S, Manchinu MF, Marongiu MF, et al. Klf1 affects DNase II-alpha expression in the central macrophage of a fetal liver erythroblastic island: a non-cell-autonomous role in definitive erythropoiesis. Mol Cell Biol. 2011;31:4144–4154. doi:10.1128/MCB.05532-11
   PubMed Web of Science ®Google Scholar
• Hanspal M, Hanspal JS. The association of erythroblasts with macrophages promotes erythroid proliferation and maturation: a 30-kD heparin-binding protein is involved in this contact. Blood. 1994;84:3494–3504. doi:10.1182/blood.V84.10.3494.3494
   PubMed Web of Science ®Google Scholar
• Mohandas N, Prenant M. Three-dimensional model of bone marrow. Blood. 1978;51:633–643. doi:10.1182/blood.V51.4.633.633
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–548. doi:10.1016/S1470-2045(14)70442-5
   PubMed Web of Science ®Google Scholar
• Ali AM, Huang Y, Pinheiro RF, et al. Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes. Blood Adv. 2018;2:1393–1402. doi:10.1182/bloodadvances.2018018440
   PubMed Web of Science ®Google Scholar
• Li W, Wang Y, Zhao H, et al. Identification and transcriptome analysis of erythroblastic island macrophages. Blood. 2019;134:480–491. doi:10.1182/blood.2019000430
   PubMed Web of Science ®Google Scholar
• Silvestris F, Tucci M, Cafforio P, Dammacco F. Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood. 2001;97:1155–1164. doi:10.1182/blood.v97.5.1155
   PubMed Web of Science ®Google Scholar
• Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood. 2002;99:1305–1313. doi:10.1182/blood.v99.4.1305
   PubMed Web of Science ®Google Scholar
• Sharma S, Nemeth E, Chen Y-H, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14:3262–3267. doi:10.1158/1078-0432.CCR-07-4153
   PubMed Web of Science ®Google Scholar
• Andriopoulos B, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41:482–487. doi:10.1038/ng.335
   PubMed Web of Science ®Google Scholar
• Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41:478–481. doi:10.1038/ng.320
   PubMed Web of Science ®Google Scholar
• Buck I, Morceau F, Cristofanon S, et al. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation. Biochem Pharmacol. 2008;76:1229–1239. doi:10.1016/j.bcp.2008.08.025
   PubMed Web of Science ®Google Scholar
• Grigorakaki C, Morceau F, Chateauvieux S, Dicato M, Diederich M. Tumor necrosis factor alpha-mediated inhibition of erythropoiesis involves GATA-1/GATA-2 balance impairment and PU.1 over-expression. Biochem Pharmacol. 2011;82:156–166. doi:10.1016/j.bcp.2011.03.030
   PubMed Web of Science ®Google Scholar
• Pavese I, Satta F, Todi F, et al. High serum levels of TNF-alpha and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients. Ann Oncol. 2010;21:1523–1528. doi:10.1093/annonc/mdp568
   PubMedGoogle Scholar
• Pasqualetti P, Collacciani A, Casale R. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes. Eur Rev Med Pharmacol Sci. 2000;4:111–115.
   PubMedGoogle Scholar
• Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol. 1992;82:648–653. doi:10.1111/j.1365-2141.1992.tb06939.x
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest. 2005;35(Suppl 3):32–35. doi:10.1111/j.1365-2362.2005.01528.x
   PubMed Web of Science ®Google Scholar
• Jin SH, Lee JE, Yun J-H, et al. Isolation and characterization of human mesenchymal stem cells from gingival connective tissue. J Periodontal Res. 2015;50:461–467. doi:10.1111/jre.12228
   PubMed Web of Science ®Google Scholar
• Wang LH, Yang XY, Zhang X, et al. Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells. Immunity. 2004;20:205–218. doi:10.1016/s1074-7613(04)00030-5
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Honemann D, Lentzsch S, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood. 2002;100:3311–3318. doi:10.1182/blood-2002-01-0102
   PubMed Web of Science ®Google Scholar
• Georgii-Hemming P, Strömberg T, Janson ET, et al. The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. Blood. 1999;93:1724–1731.
   PubMed Web of Science ®Google Scholar
• Spets H, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood. 1998;92:2914–2923. doi:10.1182/blood.V92.8.2914
   PubMed Web of Science ®Google Scholar